In the B16 melanoma tumor model, the treatment with CBs and ISAV CBs do not change the tumor growth (Figure 5B), with a significant decrease in CD8 TILs (Figure 5C) on B16-ISAV treated mice. Here, CD8A is linked to neoplasm.